Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340398 | 0.90 | PRCP (0.58) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL1717271 | 0.86 | PRCP (0.65) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL1009943 | 0.83 | PRCP (0.64) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL5898800 | 0.83 | PRCP (0.61) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL27896744 | 0.82 | PRCP (0.40) | PRCPSLC22A1ALDH1A1KDM4EMAPT | |
| SCHEMBL13977536 | 0.80 | PRCP (0.67) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL28048653 | 0.80 | PRCP (0.71) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL27985631 | 0.80 | PRCP (0.60) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL16235943 | 0.80 | PRCP (0.57) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL9533144 | 0.79 | PRCP (0.59) | PRCPSLC22A1OPRM1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | claimed |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | claimed |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | claimed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | claimed |
| WO-2017160632-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | claimed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | claimed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-8202883-B2 | Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases | AETERNA ZENTARIS GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| CN-1209125-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | PRCP 1705/4885SLC22A1 752/4885OPRM1 4733/4885 |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | MPO, NOX5, SERPINB1 | PRCP 44/4885SLC22A1 4045/4885OPRM1 1516/4885 |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | PRCP 88/4885SLC22A1 4287/4885OPRM1 1170/4885 |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | PRCP 1502/4885SLC22A1 4113/4885OPRM1 4496/4885 |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | PRCP 723/4885SLC22A1 685/4885OPRM1 408/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | PRCP 88/4885SLC22A1 4287/4885OPRM1 1170/4885 |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | MPO, NOX5, SERPINB1 | PRCP 44/4885SLC22A1 4045/4885OPRM1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.